TABLE 4.

In vitro susceptibilities to fluconazole and voriconazole of 814 yeast strain isolates in the CHIF-NET study, 2010

Organism	In vitro susceptibilitya to:
	Fluconazole		Voriconazole
	% S	% R	% S	% R
C. albicans	99.3	0.4	99.3	0.7
C. parapsilosis complex
C. parapsilosis sensu stricto	98.6	1.4	100	0
C. metapsilosis	100	0	100	0
C. orthopsilosis	100	0	100	0
L. elongisporus	100	0	100	0
C. tropicalis	94.3	5.7	94.3	5.7
C. glabrata complex
C. glabrata sensu stricto	NAb	12.2	82.2c	17.8c
C. nivariensis	NA	0	100c	0c
C. krusei	0	100	83.3	11.1
C. guilliermondii	100	0	100	0
C. pelliculosa	50.0	33.3	66.7	8.3
C. lipolytica	10.0	90.0	10.0	90.0
C. lustitaniae	83.3	0	100	0
C. quercitrusa	0	100	100	0
C. catenulata	0	100	0	100
C. fabianii	100	0	100	0
C. famata	100	0	100	0
C. haemulonii	100	0	100	0
C. kefyr	100	0	100	0
C. norvegensis	100	0	100	0
C. neoformans	90.5	6.3	100	0
Other yeast species
Geotrichum capitum	100	0	100	0
Kodamaea ohmeri	100	0	100	0
Meyerozyma caribbica	100	0	100	0
Rhodotorula mucilaginosa	0	100	0	100
Trichosporon asahii	85.7	0	100	0
Trichosporon dermatis	100	0	100	0

^aSusceptibility data were interpreted (i) by species-specific interpretive criteria for C. albicans, C. tropicalis, C. parapsilosis complex, the C. glabrata complex, and C. krusei as described by Pfaller et al. (27, 28) and (ii) in accordance with CLSI document M44-S3 (8) for other yeast species.

^bThe latest species-specific interpretive criteria for C. glabrata complex susceptibility to fluconazole were defined as ≤14 mm for R and ≥15 mm for S-DD (28); thus, category S is not applicable (NA) to the C. glabrata complex.

^cAs CBPs for C. glabrata complex susceptibility to voriconazole are not available, the ECV (a zone diameter of ≥16 mm) was used to differentiate wild-type (listed in category S) from non-wild-type (listed in category R) strains of this complex, as described by Pfaller et al. (27).